The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -19.86 — distress zone — historically elevated failure riskWatch
Leadership changes
From Akari Therapeutics Plc's own filings, the day they're filed.
- Samir R. Patel · Chief Executive Officer · departureeff. 2025-04-14
- Michael Grissinger · Director · departureeff. 2024-12-16
- Wendy DiCicco · Chief Financial Officer · departureeff. 2024-12-06
Latest filings
- DEF 14A · Annual proxy (pay & governance)2026-06-04
- 8-K · Company announcement2026-05-22
- 10-Q · Quarterly report2026-05-19
- 10-K · Annual report2026-03-30
- 8-K · Company announcement2026-03-17
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Akari Therapeutics Plc, every answer cited🔒
- The Intelligence Brief — added when Akari Therapeutics Plc's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.